Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

BACKGROUND: To date, no immunological data on COVID-19 heterologous vaccination schedules in humans have been reported. We assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, As...

Descripción completa

Detalles Bibliográficos
Autores principales: Borobia, Alberto M, Carcas, Antonio J, Pérez-Olmeda, Mayte, Castaño, Luis, Bertran, María Jesús, García-Pérez, Javier, Campins, Magdalena, Portolés, Antonio, González-Pérez, María, García Morales, María Teresa, Arana-Arri, Eunate, Aldea, Marta, Díez-Fuertes, Francisco, Fuentes, Inmaculada, Ascaso, Ana, Lora, David, Imaz-Ayo, Natale, Barón-Mira, Lourdes E, Agustí, Antonia, Pérez-Ingidua, Carla, Gómez de la Cámara, Agustín, Arribas, José Ramón, Ochando, Jordi, Alcamí, José, Belda-Iniesta, Cristóbal, Frías, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233007/
https://www.ncbi.nlm.nih.gov/pubmed/34181880
http://dx.doi.org/10.1016/S0140-6736(21)01420-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233007/
https://www.ncbi.nlm.nih.gov/pubmed/34181880
http://dx.doi.org/10.1016/S0140-6736(21)01420-3

Ejemplares similares